Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for RAS wild-type metastatic colorectal cancer patients based on the TAILOR trial

Huijuan Wang, Lingfei Huang, Peng Gao, Zhengyi Zhu, Weifeng Ye, Haiying Ding & Luo Fang
Objectives Cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomized, multicentre, phase III trial. Nevertheless, the cost-effectiveness of these two regimens remains uncertain. The following study aims to determine whether cetuximab combined with FOLFOX-4 is a cost-effective strategy for specific RAS wt mCRC patients in China. Design A...
71 views reported since publication in 2020.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
10 downloads reported since publication in 2020.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?